CA2278848A1 - Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use - Google Patents

Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use Download PDF

Info

Publication number
CA2278848A1
CA2278848A1 CA002278848A CA2278848A CA2278848A1 CA 2278848 A1 CA2278848 A1 CA 2278848A1 CA 002278848 A CA002278848 A CA 002278848A CA 2278848 A CA2278848 A CA 2278848A CA 2278848 A1 CA2278848 A1 CA 2278848A1
Authority
CA
Canada
Prior art keywords
seq
grafted
nucleic acid
referenced
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002278848A
Other languages
English (en)
French (fr)
Inventor
William D. Huse
Scott M. Glaser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Applied Molecular Evolution Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2278848A1 publication Critical patent/CA2278848A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002278848A 1997-01-30 1998-01-30 Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use Abandoned CA2278848A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/791,391 US6590079B2 (en) 1997-01-30 1997-01-30 Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US08/791,391 1997-01-30
PCT/US1998/001826 WO1998033919A2 (en) 1997-01-30 1998-01-30 Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use

Publications (1)

Publication Number Publication Date
CA2278848A1 true CA2278848A1 (en) 1998-08-06

Family

ID=25153592

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002278848A Abandoned CA2278848A1 (en) 1997-01-30 1998-01-30 Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use

Country Status (6)

Country Link
US (2) US6590079B2 (cg-RX-API-DMAC10.html)
EP (1) EP0970217A2 (cg-RX-API-DMAC10.html)
JP (1) JP2001511149A (cg-RX-API-DMAC10.html)
AU (1) AU737569B2 (cg-RX-API-DMAC10.html)
CA (1) CA2278848A1 (cg-RX-API-DMAC10.html)
WO (1) WO1998033919A2 (cg-RX-API-DMAC10.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US20010011125A1 (en) * 1997-01-30 2001-08-02 William D. Huse Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use
IL143514A0 (en) * 1998-12-04 2002-04-21 Novartis Ag METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ3
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US6531580B1 (en) * 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
IL148841A0 (en) * 1999-10-06 2002-09-12 Basf Ag INHIBITORS OF THE ENDOTHELIN SIGNALLING PATHWAY AND αvβ3 INTEGRIN RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US20010034062A1 (en) * 2000-02-09 2001-10-25 Scott Koenig Antibody gene therapy with adeno-associated viral vectors
JP2003525061A (ja) * 2000-03-01 2003-08-26 メディミューン,インコーポレイテッド 高効力組換え抗体およびその産生法
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
NZ528076A (en) * 2001-03-02 2005-09-30 Medimmune Inc Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists with an immunomodulatory agents, anti-inflammatory agents, TNF-alpha antagonists or CD2 binding molecules
CN1247258C (zh) * 2001-04-24 2006-03-29 默克专利有限公司 使用抗血管生成剂和TNFα的联合疗法
PL370080A1 (en) * 2001-10-10 2005-05-16 Pharmacia Italia Spa Methods for preventing and treating bone loss with steroid compounds
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
JP2005533001A (ja) * 2002-03-04 2005-11-04 メディミューン,インコーポレーテッド インテグリンαvβ3アンタゴニストを他の物質と併用投与する癌の予防または治療方法
EP1513879B1 (en) * 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
JP2006516636A (ja) * 2003-01-30 2006-07-06 メディミューン,インコーポレーテッド 抗インテグリンαvβ3抗体製剤及びその用途
EP1596884A2 (en) * 2003-01-30 2005-11-23 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
GB0302699D0 (en) * 2003-02-06 2003-03-12 Univ Bradford Immunoglobulin
KR101224235B1 (ko) 2003-04-11 2013-01-25 메디뮨 엘엘씨 재조합 il­9 항체 및 그의 용도
US7351739B2 (en) 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
ATE461708T1 (de) * 2004-05-07 2010-04-15 Univ North Carolina Verfahren zur verstärkung oder hemmung des insulinähnlichen wachstumsfaktors-i
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
AU2005277641A1 (en) * 2004-08-16 2006-03-02 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
WO2006047639A2 (en) 2004-10-27 2006-05-04 Medimmune, Inc. Modulation of antibody specificity by tailoring the affinity to cognate antigens
EP1819732A2 (en) 2004-12-06 2007-08-22 Kirin Beer Kabushiki Kaisha Human monoclonal antibodies to influenza m2 protein and methods of making and using same
ES2547463T3 (es) 2005-06-17 2015-10-06 Merck Sharp & Dohme Corp. Moléculas de unión a ILT3 y usos de las mismas
KR20080025174A (ko) 2005-06-23 2008-03-19 메디뮨 인코포레이티드 응집 및 단편화 프로파일이 최적화된 항체 제제
WO2008094176A2 (en) * 2006-06-19 2008-08-07 Tolerx, Inc. Ilt3 binding molecules and uses therefor
AU2007272970C1 (en) 2006-07-11 2013-01-10 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
PT2068889T (pt) 2006-08-10 2020-01-30 Roy C Levitt Anakinra para uso no tratamento da síndrome da bronquiolite obliterante
EP2064335A4 (en) 2006-10-16 2011-03-30 Medimmune Llc MOLECULES WITH REDUCED HALF TIME, COMPOSITIONS AND ITS USE
US20100197896A1 (en) * 2007-05-16 2010-08-05 Leung Shui-On Functional humanization of complementarity determining regions (cdrs)
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8633139B2 (en) 2007-12-21 2014-01-21 Abbvie Biotherapeutics Inc. Methods of screening complex protein libraries to identify altered properties
JP2011524179A (ja) 2008-06-16 2011-09-01 パトリス リミテッド Lm−1抗体、機能性フラグメント、lm−1標的抗原、ならびにそれらを作製および使用するための方法
EP2437767B1 (en) 2009-06-01 2015-07-08 MedImmune, LLC Molecules with extended half-lives and uses thereof
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
HUE037186T2 (hu) 2011-12-28 2018-08-28 Immunoqure Ag Eljárás humán antitestek izolálására
HK1213904A1 (zh) 2012-08-31 2016-07-15 The University Of North Carolina At Chapel Hill 用於增强或抑制胰島素樣生長因子1(igf-1)的單克隆抗體
CA2917112C (en) 2013-07-03 2022-07-05 Immunoqure Ag Human anti-ifn-alpha antibodies
US20200109205A1 (en) 2017-03-31 2020-04-09 The Regents Of The University Of California Compositions and methods for targeting and killing alpha-v beta-3-positive cancer stem cells (cscs) and treating drug resistant cancers
KR102098462B1 (ko) * 2018-03-14 2020-04-08 가톨릭대학교 산학협력단 αvβ3 인테그린 표적 단일 도메인 항체
WO2021168000A1 (en) * 2020-02-17 2021-08-26 University Of Virginia Patent Foundation CAR T CELLS TARGETING THE INTEGRIN ALPHAv BETA3 EXHIBIT ROBUST ANTI-TUMOR RESPONSES AGAINST GLIOMAS AND OTHER SOLID TUMOR MALIGNANCIES

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
DE69322860T2 (de) * 1992-04-03 1999-07-01 Genentech, Inc., South San Francisco, Calif. Antikörper gegen alpha v beta 3 integrin
IT1268004B1 (it) * 1994-02-02 1997-02-20 Giuseppe Lambertini Dispositivo per il bloccaggio di un pezzo su un piano d'appoggio, quale una tavola di macchina operatrice.
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
WO1996040250A2 (en) 1995-06-07 1996-12-19 Centocor, Inc. Platelet-specific chimeric immunoglobulin and methods of use therefor
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same

Also Published As

Publication number Publication date
WO1998033919A2 (en) 1998-08-06
US6590079B2 (en) 2003-07-08
JP2001511149A (ja) 2001-08-07
AU6139198A (en) 1998-08-25
US20030208048A1 (en) 2003-11-06
US20010016645A1 (en) 2001-08-23
EP0970217A2 (en) 2000-01-12
US7422744B2 (en) 2008-09-09
AU737569B2 (en) 2001-08-23
WO1998033919A3 (en) 1998-12-17

Similar Documents

Publication Publication Date Title
AU781501C (en) Anti-alphavbeta3recombinant human antibodies, nucleic acids encoding same and methods of use
AU737569B2 (en) Anti-alphav-beta3 recombinant human antibodies, nucleic acids encoding same and methods of use
US7422745B2 (en) Methods of treating cancer with vαβ3-specific antibodies
US20080160576A1 (en) Anti-alphabeta3 humanized monoclonal antibodies
HUE025608T2 (en) Human monoclonal antibody against activin receptor-like kinase-1 (ALK-1)
WO1998040488A9 (en) Anti-alphabeta3 humanized monoclonal antibodies
US20010011125A1 (en) Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead